Another trial is studying spartalizumab combined with either canakinumab, the anti-IL17A monoclonal antibody CJM112 or trametinib in NSCLC, CRC and triple-negative breast cancer (TNBC) (ClinicalTrials.gov identifier: NCT02900664). The gene discussed is IL17A; the disease is colorectal carcinoma.